Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 461 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Plaque Psoriasis Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

NCT04571567
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab
Drug
Lead sponsor
Saakshi Khattri
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

NCT02949388
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 30, 2026, 5:06 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

NCT03556202
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

NCT03167515
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
074-6751 Lotion
Device
Lead sponsor
Ferndale Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Carmel, Indiana • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06176768
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LY3972406, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 30, 2026, 5:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Birmingham, Alabama • Encinitas, California • Encino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

NCT02576678
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

NCT00820950
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211389
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
ARQ-151 0.3% cream, ARQ-151 vehicle cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03897075
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Interventions
Tildrakizumab, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Not listed Phase 1Phase 2 Interventional

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

NCT01670513
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Low Strength, IDP-118 High Strength
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Santa Rosa, California • Clinton Township, Michigan • Fort Gratiot, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

NCT01205880
View directory record Official record
Conditions
Psoriasis
Interventions
Calcitriol ointment, Clobetasol spray
Drug
Lead sponsor
Emer, Jason, M.D.
Individual
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

NCT00192452
View directory record Official record
Conditions
Psoriasis
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
3
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2006 · Synced Sep 30, 2026, 5:06 AM EDT
Active, not recruiting Phase 3 Interventional

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

NCT05172726
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years to 17 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Rogers, Arkansas • Fountain Valley, California • Rancho Santa Margarita, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211363
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Roflumilast 0.3% cream, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Results available

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Sep 30, 2026, 5:06 AM EDT
Completed No phase listed Observational

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

NCT00437216
View directory record Official record
Conditions
Psoriasis
Interventions
Clobetasol Propionate, 0.05%, Clobetasol propionate, 0.05% Spray
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Cedar Knolls, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Sep 30, 2026, 5:06 AM EDT
Recruiting Phase 4 Interventional

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

NCT03987763
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-122 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Fountain Valley, California • Thousand Oaks, California • Doral, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

NCT02387801
View directory record Official record
Conditions
Psoriasis
Interventions
Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

NCT00236119
View directory record Official record
Conditions
Psoriasis
Interventions
CEP-701 20mg, CEP-701 40mg, CEP-701 60mg, CEP-701 80mg
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Dallas, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis

NCT00419666
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Calcitriol 3mcg/g
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • San Diego, California • Eagan, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

NCT03073200
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Placebo, Etanercept
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

NCT03230292
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
High Point, North Carolina • Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Sep 30, 2026, 5:06 AM EDT